Drug development can be a gas

Pharmaceutical and biotech industries are heavily dependent on gas mixtures to grow biological cultures
The pharmaceutical and biotech industries rely heavily on industrial gases for applications such as supercritical fluid chromatgraphy and lyophilisation. Gas supply systems theefore need to offer high purity and traceability through the supply chain
http://www.manufacturingchemist.com/technical/article_page/Drug_development_can_be_a_gas/87137
Novartis Japan Achieves Primary Endpoint In HER2 Positive Advanced Breast Cancer Phase III Afinitor Trials
![]()
Everolimus
Novartis announced it achieved its primary endpoint of significantly extending progression-free survival with Afinitor (everolimus) in Phase III trials of patients with HER2 positive advanced breast cancer.
read all at
Everolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).
It is currently used as an immunosuppressant to prevent rejection of organ transplants and treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors for use in a number of cancers.
It is marketed by Novartis under the tradenames Zortress (USA) and Certican (Europe and other countries) in transplantation medicine, and Afinitor in oncology.
GSK’s Votrient meets primary objective in Phase III ovarian cancer trial
![]()
pazopanib
GlaxoSmithKline’s (GSK) Votrient (pazopanib) has met the primary objective of a statistically significant improvement in the time to disease progression or death that is the progression-free survival (PFS) against placebo in Phase III ovarian cancer..
Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptortyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by the U.S. Food and Drug Administration.Pazopanib may also be active in ovarian cancer Pazopanib also appears effective in the treatment of non-small cell lung carcinoma.
New Drug Target Identified For Treating Deadly Form Of Leukemia
A research team in Singapore has identified a promising drug target for the treatment of patients with terminal-stage chronic myeloid leukemia (CML).
AsianScientist (Jun. 4, 2013) – A research team in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia (CML). The discovery makes it possible to develop drugs that may extend the survival of patients suffering from this deadly form of leukemia.read all this at
http://www.asianscientist.com/in-the-lab/new-drug-target-deadly-form-leukemia-2013/
New Rule on Importing Active Pharmaceutical Ingredients (API) to the EU
READ ALL AT
http://ec.europa.eu/health/files/documents/active_pharmaceutical_
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
New Drug Ganetespib May Help Fight Certain Advanced Lung Cancers

ganetespib
STA 9090, cas no 888216-25-9
read all at
http://www.drugs.com/news/new-may-help-fight-certain-advanced-lung-cancers-44819.html
by
WORLD DRUG TRACKER
DR ANTHONY CRATO
Flamel Technologies today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for Bloxiverz (neostigmine methylsulfate)
![]()
Neostigmine
Flamel Technologies Announces FDA Approval of Bloxiverz
06/03/2013 — Flamel Technologies today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for Bloxiverz (neostigmine methylsulfate), a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Flamel expects to launch Bloxiverz in July 2013 in 0.5 and 1.0 mg/mL strengths
Chemistry
Neostigmine, N,N,N-trimethyl-meta-(dimethylcarbomoyloxy)-phenylammonium methylsulfonate, which can be viewed as a simplified analog of physostigmine, is made by reacting 3-dimethylaminophenol with N-dimethylcarbamoyl chloride, which forms the dimethylcarbamate, and its subsequent alkylation using dimethylsulfate forming the desired compound. ![]()
- J.A. Aeschlimann, U.S. Patent 1,905,990 (1933).
Neostigmine shows notable UV/VIS absorption at 261nm, 267nm, and 225nm.
Neostigmine’s 1H NMR Spectroscopy reveals shifts at: 7.8, 7.7, 7.4, 7.4, 3.8, and 3.1 parts per million. The higher shifts are due to the aromatic hydrogens. The lower shifts at 3.8ppm and 3.1ppm are due to the electronic withdrawing nature of the tertiary and quarterary nitrogen, respectively.
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
All Yоu Nееd Tо Knоwn Abоut Hepatitis C
All Yоu Nееd Tо Knоwn Abоut Hepatitis C
Thе mоѕt fearsome оf аll types оf hepatitis іѕ thе hepatitis C. Thіѕ disease, hepatitis C hаѕ bееn considered bу mаnу specialists tо bе аn epidemic. It іѕ аlѕо knоwn аѕ а silent illness, bесаuѕе уоu саn gеt hepatitis C fоr mаnу years аnd nоt еvеn knоw that. Studies hаvе аlѕо shown thаt аlmоѕt а thіrd оf chronic hepatits C patients will, аt ѕоmе point, suffer frоm symptoms thаt mау threaten thеіr lives.
Hepatitis C саn bе developed bу infection wіth thе hepatitis C virus, whісh аt fіrѕt wаѕ related tо intravenous drugs оr blood transfusions. Mаnу years аftеr thе hepatitis C affected people, іtѕ extent wаѕ knоw fоr а fact. Thаt happened whеn thе fіrѕt blood test fоr detecting thе hepatitis C virus wаѕ available. Mаnу studies hаvе shown thаt іn thе fіrѕt years оf hepatitis C, mоrе thаn а thіrd оf thе patients developed cirrhosis аnd…
View original post 333 more words
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....











